FILED

SEP 1 9 2002

STATE OF NEW JERSEY
DEPARTMENT OF LAW & PUBLIC SAFETY
DIVISION OF CONSUMER AFFAIRS
STATE BOARD OF PHARMACY

BOARD OF PHARMACY

IN THE MATTER OF THE SUSPENSION OR REVOCATION OF THE LICENSE OF

Administrative Action

CONSENT ORDER

JOHN WALKER, R.P.

TO PRACTICE PHARMACY IN THE STATE OF NEW JERSEY

This matter was originally opened to the New Jersey State
Board of Pharmacy by John J. Farmer, Attorney General of New Jersey,
Marianne W. Greenwald, Deputy Attorney General appearing.

Respondent entered into a consent Order with the Board of Pharmacy on June 22, 2000 whereby he agreed to the voluntary surrender of his pharmacy license pending further Order of the Board upon respondent's application for relicensure.

Respondent appeared before the full Board on April 10, 2002 and testified as to his past treatment for substance abuse and his present efforts to maintain his sobriety.

It appearing that respondent has completed a treatment program, continues to attend support group meetings, is under the care of a therapist and continues to have negative drug and alcohol screens, and respondent having satisfied the Board of his intention to continue in his present treatment program, and it further appearing that respondent wishes to resolve this matter without the necessity of further formal proceedings, and for good cause shown,

IT IS THEREFORE on this 19th day of September, 2002, ORDERED AND AGREED,

- 1. Respondent shall submit documentation of his successful completion of 30 continuing education credits. Thereafter, the license to practice pharmacy of John Walker shall be reinstated and placed on a probationary status for two (2) years subject to compliance with paragraphs 2 through 9 herein. If respondent violates any of the provisions of paragraphs 2 through 9 herein, the Board may initiate proceedings to revoke his license to practice pharmacy.
- 2. (a) John Walker shall submit to random urine sampling once a week at a laboratory facility approved by the Board for the duration of the probation. The urine monitoring shall be conducted with direct witnessing of the taking of the samples as designed by the laboratory facility. The initial drug screen shall utilize appropriate screening techniques and all confirming tests and/or secondary tests will be performed by gas/chromatography/mass spectrometry (G.C./M.S.). The testing procedure shall include a forensic chain of custody protocol to ensure sample integrity and to provide documentation in the event of a legal challenge.
- (b) All test results shall be provided to Deborah Whipple, Executive Director of the Board, or her designee in the event she is unavailable. The Board also will retain sole discretion to modify the manner of testing in the event technical developments or individual requirements indicate that a different

methodology or approach is required in order to guarantee the accuracy and reliability of the testing.

- Any failure by respondent to submit or provide a urine sample within twenty-four (24) hours of a request will be deemed to be equivalent to a confirmed positive urine test. In the event respondent is unable to appear for a scheduled urine test or provide a urine sample due to illness or other impossibility, consent to waive that day's test must be secured from Deborah Whipple, or her designee. Personnel at the lab facility shall not be authorized to waive a urine test. In addition, respondent must provide the Board with written substantiation of his inability to appear for a test within two (2) days, e.g., a physician's report attesting that he was so ill that he was unable to provide the urine sample or appear for the test. "Impossibility" as employed in this provision shall mean an obstacle beyond the control of respondent that is so insurmountable or that makes appearance for the test or provision of the urine sample so infeasible that a reasonable person would not withhold consent to waive the test on that day.
- (d) In the event respondent will be out of the State for any reason, the Board shall be so advised so that arrangements may be made at the Board's discretion for alternate testing. The Board may, in its sole discretion, modify the frequency of testing or method of testing during the monitoring period.

- (e) Any urine test result showing creatinine levels below 20 mg/dL and a specific gravity below 1.009 shall be deemed a confirmed positive urine test.
- (f) Respondent shall familiarize himself with all foods, food additives or other products (such as poppy seeds) which may affect the validity of urine screens, be presumed to possess that knowledge, and shall refrain from the use of such substances. Ingestion of such substances shall not be an acceptable reason for a positive urine screen and/or failure to comply with the urine monitoring program.
- 3. Respondent shall continue his participation with the Physicians' Health Program ("PHP") and shall have monthly face to face contact with representatives from that program. Respondent shall comply with after care as directed by the PHP and shall comply with any recommended therapeutic regime for treatment or counseling. Respondent shall be responsible for ensuring that any treating psychologist and any other person(s) providing therapy for his addiction provide the board with quarterly reports regarding his progress in counseling.
- 4. Respondent shall attend support groups, including NA or AA not less than three (3) times per week. Respondent shall provide evidence of attendance at such groups directly to the Board. If respondent has discontinued attendance at any of the support groups without obtaining approval of the Board, he shall be deemed in violation of this Order.

- 5. Respondent shall abstain from the use of alcohol and controlled dangerous substances and shall not possess any controlled dangerous substances except pursuant to a bona fide prescription written by a physician or dentist for good medical or dental cause in his own treatment. In addition, respondent shall advise any and all treating physicians and/or dentists of his history of substance abuse. Respondent shall cause any physician or dentist who prescribes medication which is a controlled dangerous substance to provide a written report to the Board together with patient records indicating the need for such medication. Such report shall be provided to the Board no later that two (2) days subsequent to the prescription in order to avoid confusion which may be caused by a confirmed positive urine test as a result of such medication.
- 6. Respondent shall provide any and all releases to any and all parties who are participating in the monitoring, treating or other program as outlined in this order, as may be required in order that all reports, records, and other pertinent information may be provided to, and utilized by the Board in a timely manner.
- 7.(a) Respondent shall be subject to an order of automatic suspension of his license upon the Board's receipt of any information which the Board, in its sole discretion, deems reliable demonstrating that respondent has failed to comply with any of the conditions set forth in this consent order, including but not limited to report of a confirmed positive urine, or a <u>prima facie</u> showing of a relapse or recurrence of alcohol or drug abuse.

- (b) Respondent shall have a right to apply for removal of the automatic suspension on ten (10) days notice to the Board and to the Attorney General. The Board may hold a hearing on that application before the full Board or before a committee of the Board. In the event a committee hears the application, its action shall be subject to ratification of the full Board at its next scheduled meeting. In a hearing seeking removal of the automatic suspension, any confirmed positive urine shall be presumed valid.
- 8. Respondent shall not be a pharmacist-in-charge during the entire period of probation.
- 9. Respondent shall give written notice to the Board prior to beginning or changing any employment.

NEW JERSEY STATE BOARD OF PHARMACY

D 17 -

Anthony Alex

President

I have read the within Order and understand it. I agree to be bound by its terms and hereby consent to it being entered by the New Jersey Board of Pharmacy.

John Walker, R.